Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DelMar Pharmaceuticals Inc.

www.delmarpharma.com

Latest From ADC Therapeutics SARL

Biopharma Quarterly Dealmaking Statistics, Q4 2016

Biopharma companies closed out 2016 with $9.6 billion in financing, the strongest quarter of the year. M&A deals reached $12.2 billion in value, led by Lonza's takeover of Capsugel; most of the fourth quarter's largest partnerships were built around innovative platforms in antibodies, peptides and gene therapy.

BioPharmaceutical Deals

Venture Funding Deals: ADC Therapeutics, Unity Biotech Raise $100m-Plus

ADC Therapeutics and Unity Biotechnology close $100m-plus VC rounds, while Carrick comes close with a $95m debut. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in September and October 2016.

StartUps and SMEs Financing

ADC Therapeutics Raises $105m To Reach Pivotal Studies

A second round of funding in just over a year is expected to allow the Lausanne, Switzerland-based company to reach the start of pivotal studies for its novel antibody-drug conjugates.

Financing Cancer

Deal Watch: NASH In The Hot Seat

Regeneron stayed busy during the past two weeks, collaborating and making an equity commitment to CRISPR gene-editing biotech Intellia and signing an immuno-oncology deal with MedImmune. Allergan bounced off the termination of its merger with Pfizer by partnering with Heptares in neurological disease.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • DelMar Pharmaceuticals BC Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • DelMar Pharmaceuticals Inc.
  • Senior Management
  • Jeffrey Bacha, Pres. & CEO
    Scott Praill, CFO
    Dennis Brown, PhD, CSO
  • Contact Info
  • DelMar Pharmaceuticals Inc.
    Phone: (604) 629-5989
    999 West Broadway
    Ste. 720
    Vancouver, V5Z 1K5
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register